EP1924596A4 - Albumin fusion proteins - Google Patents
Albumin fusion proteinsInfo
- Publication number
- EP1924596A4 EP1924596A4 EP06813242A EP06813242A EP1924596A4 EP 1924596 A4 EP1924596 A4 EP 1924596A4 EP 06813242 A EP06813242 A EP 06813242A EP 06813242 A EP06813242 A EP 06813242A EP 1924596 A4 EP1924596 A4 EP 1924596A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion proteins
- albumin fusion
- albumin
- proteins
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1924596A2 EP1924596A2 (en) | 2008-05-28 |
| EP1924596A4 true EP1924596A4 (en) | 2009-07-29 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06813242A Withdrawn EP1924596A4 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (en) |
| JP (1) | JP2009504157A (en) |
| KR (1) | KR20080071119A (en) |
| AU (1) | AU2006280312A1 (en) |
| BR (1) | BRPI0614761A2 (en) |
| CA (1) | CA2618476A1 (en) |
| EC (1) | ECSP088262A (en) |
| IL (1) | IL189246A0 (en) |
| MA (1) | MA29836B1 (en) |
| MX (1) | MX2008001865A (en) |
| NO (1) | NO20081233L (en) |
| TN (1) | TNSN08064A1 (en) |
| WO (1) | WO2007021494A2 (en) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| ES2545090T3 (en) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Albumin and GCSF fusion proteins |
| AU2005211725B2 (en) | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007146038A2 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BRPI0716744A2 (en) * | 2006-09-14 | 2016-10-04 | Human Genome Sciences Inc | albumin fusion proteins |
| WO2008094538A2 (en) | 2007-01-30 | 2008-08-07 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| WO2009150284A2 (en) | 2008-06-13 | 2009-12-17 | Proyecto De Biomedicina Cima, S.L. | Apo-a conjugates for the administration of biologically active compounds |
| SG172940A1 (en) | 2009-01-16 | 2011-08-29 | Teva Pharma | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
| JP5936112B2 (en) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | Albumin variants and complexes |
| KR20100100254A (en) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent |
| AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
| GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
| CN106977608A (en) | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | Albumin derivant and variant |
| CN103124788B (en) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | Bispecific fusion protein |
| KR101969526B1 (en) * | 2011-02-28 | 2019-04-17 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | Medicinal agent for inhibiting metastasis of malignant tumor |
| CN110272484A (en) | 2011-05-05 | 2019-09-24 | 阿尔布梅迪克斯医疗有限公司 | Albumin variants |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE202012012956U1 (en) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | A combination of at least two direct-acting antiviral agents for use in the treatment of HCV, comprising ribavirin but not interferon |
| UY34401A (en) | 2011-10-21 | 2013-05-31 | Abbvie Inc | METHODS FOR HCV TREATMENT |
| WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| BR112014017165B1 (en) | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| WO2013122617A1 (en) | 2012-02-15 | 2013-08-22 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
| CN104736559B (en) | 2012-03-16 | 2022-04-08 | 阿尔布梅迪克斯医疗有限公司 | Albumin variants |
| CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
| JP2015521589A (en) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Procoagulant compounds |
| CN103525695B (en) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | Portable kidney function detecting system |
| EP4269431A1 (en) | 2012-07-11 | 2023-11-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
| PL3889173T3 (en) | 2013-02-15 | 2023-12-11 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
| EP3318124A3 (en) | 2013-02-16 | 2018-05-30 | Albumedix A/S | Pharmacokinetic animal model |
| CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| BR112016015512B1 (en) | 2014-01-10 | 2023-12-19 | Bioverativ Therapeutics Inc | CHIMERICAL PROTEIN, PHARMACEUTICAL COMPOSITION AND ITS USES |
| EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
| JP6625627B2 (en) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using the same |
| MA40835A (en) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES |
| MA40861A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES |
| CN108472337B (en) | 2015-08-03 | 2022-11-25 | 比奥贝拉蒂治疗公司 | Factor IX fusion proteins and methods of making and using same |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| JP7005019B2 (en) | 2015-10-02 | 2022-02-04 | シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド | Bispecific therapeutic protein for tissue repair |
| CN105254766B (en) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression |
| SG10201913278PA (en) | 2016-02-01 | 2020-02-27 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| JP2020500306A (en) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | Identification and treatment of tumors characterized by neonatal Fc receptor overexpression |
| KR20190091292A (en) | 2016-12-02 | 2019-08-05 | 바이오버라티브 테라퓨틱스 인크. | How to Induce Immune Resistance to Coagulation Factors |
| BR112019011115A2 (en) | 2016-12-02 | 2019-10-01 | Bioverativ Therapeutics Inc | methods for treating hemophilic arthropathy using chimeric clotting factors |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| EP3576762A1 (en) | 2017-01-31 | 2019-12-11 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| MA50141A (en) * | 2017-04-20 | 2020-07-29 | Novo Nordisk As | ALBUMIN FUSION PROTEIN PURIFICATION PROCESSES |
| EP3665289A1 (en) | 2017-08-09 | 2020-06-17 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
| MX2020008152A (en) | 2018-02-01 | 2020-11-24 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor viii. |
| CA3108799A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| AU2019393880A1 (en) | 2018-12-06 | 2021-07-15 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor IX |
| EP4038182A1 (en) | 2019-09-30 | 2022-08-10 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| WO2022030580A1 (en) * | 2020-08-06 | 2022-02-10 | 国立大学法人宮崎大学 | Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof |
| WO2024080306A1 (en) * | 2022-10-11 | 2024-04-18 | Ｊｃｒファーマ株式会社 | Fusion protein of serum albumin and physiologically-active protein |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/en not_active IP Right Cessation
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/en not_active Application Discontinuation
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/en not_active Withdrawn
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en active Application Filing
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/en not_active Application Discontinuation
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/en unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/en not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009504157A (en) | 2009-02-05 |
| NO20081233L (en) | 2008-05-09 |
| IL189246A0 (en) | 2008-08-07 |
| AU2006280312A1 (en) | 2007-02-22 |
| CA2618476A1 (en) | 2007-02-22 |
| BRPI0614761A2 (en) | 2009-05-19 |
| ECSP088262A (en) | 2008-05-30 |
| WO2007021494A3 (en) | 2007-07-26 |
| WO2007021494A2 (en) | 2007-02-22 |
| TNSN08064A1 (en) | 2009-07-14 |
| KR20080071119A (en) | 2008-08-01 |
| EP1924596A2 (en) | 2008-05-28 |
| MA29836B1 (en) | 2008-10-03 |
| MX2008001865A (en) | 2008-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189246A0 (en) | Albumin fusion proteins | |
| IL176894A0 (en) | Albumin fusion proteins | |
| IL222924A0 (en) | Albumin fusion proteins | |
| IL197580A0 (en) | Albumin fusion proteins | |
| PL1830872T3 (en) | Fusion proteins | |
| GB0426397D0 (en) | Fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| EP1934372A4 (en) | Ssb - polymerase fusion proteins | |
| EP1858546A4 (en) | Modified transferrin fusion proteins | |
| ZA200801224B (en) | Albumin fusion proteins | |
| EP1594530A4 (en) | Albumin fusion proteins | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| IL187347A0 (en) | Interferon-igg fusion | |
| GB0519965D0 (en) | Joint fusion peg | |
| EP1951862A4 (en) | Cd40 ligand fusion protein vaccine | |
| ZA200901280B (en) | Exendin fusion proteins | |
| HK1118296A1 (en) | Stabilizer molecule-depleted albumin solution | |
| GB0423974D0 (en) | Proteins | |
| GB0426399D0 (en) | Fusion proteins | |
| GB0511861D0 (en) | Proteins | |
| AU2005905300A0 (en) | Fusion Protein | |
| GB0514788D0 (en) | Proteins | |
| GB0514481D0 (en) | Proteins | |
| GB0513505D0 (en) | Proteins | |
| GB0418248D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080312 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1113581 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20090626 |
|
| 17Q | First examination report despatched |
Effective date: 20100108 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120201 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1113581 Country of ref document: HK |